News

FDA accepts refiling of intravenous (IV) meloxicam for the management of moderate to severe pain.- Baudax Bio

Read time: 1 mins

Published:27th Jan 2020

Baudax Bio, Inc. a specialty pharmaceutical company focused on therapeutics for acute care settings, announced that the FDA has set a PDUFA goal date of 2 February 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain. The assignment of this PDUFA goal date follows the FDA’s acceptance of Baudax’s latest complete response package relating to its 2019 complete response letter (CRL) and appeal filing, seeking approval for IV meloxicam..

Condition: Pain:Post Surgical

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

News

FDA approval of Zynrelef indication expansion to include additional orthopedic and soft tissue procedures

Heron Therapeutics, Inc. announced that the FDA has approved its supplemental New Drug Application ("NDA") for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided

1 mins

Drug news

FDA approval of expanded approval for expanded Exparel label to include two additional nerve block indications

Pacira BioSciences, Inc. announced that the FDA has approved its supplemental new drug application (sNDA) to expand the Exparel (bupivacaine liposome injectable suspension) label to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa

1 min

Drug news

Phase III BE HEARD I and II studies of Bimzelx meet primary endpoint in Hidradenitis Suppurativa.- UCB

UCB announced positive top-line results from two Phase III studies, BE HEARD I and BE HEARD II, evaluating the efficacy and safety of Bimzelx (bimekizumab) in adults with moderate to severe hidradenitis suppurativa.

1 min

See all news